Diabetic kidney disease (DKD) is one of the greatest public health problems worldwide. The main causative entities to develop chronic kidney disease (CKD) are diabetes mellitus and or hypertension. In this regard, the coexistence of other risk factors associated to DKD such as anemia, inflammation, oxidative stress, metabolic diseases and adiposopathy contribute to the higher cardiovascular morbidity and mortality observed in these patients.

Recent evidence suggests that medication such as sodium-glucose cotransporter type 2 inhibitors (iSGLT2) or the glucagon-like peptide 1 analogs (GLP-1a) have the ability to decrease the progression of renal diseases. Moreover, these novel drugs show advantages in the cardiorenal disease field. In addition, new evidence supports the safe use of mineralocorticoid receptor antagonists (MRA) and other drugs in the control of proteinuria associated with kidney dysfunction.

Positioning nephrology at the forefront of the advancement of medicine, the aim of this Special Issue is to collate original research and review articles regarding novel cardiovascular therapeutic options for patients with DKD and its cardiovascular consequences.

Potential topics include but are not limited to the following:

• The rapid growth of chronic kidney disease (CKD) worldwide and its association with the increase in the number of diabetic patients across developed countries
• The high incidence of chronic kidney disease (CKD) derived from sedentary lifestyle and diets rich in carbohydrates
• DKD as the main cause of end stage kidney disease with the need for renal replacement therapies
• The high complexity index of CKD and how this represents an elevated consumption of economic and human resources in public health
• The investigation of novel cardiovascular risk factors, diagnostic tools, and new therapeutic agents to improve the health of this population of risk